Loading clinical trials...
Loading clinical trials...
Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo
The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.
Hyperpigmentation is a common skin condition in which the color of the skin becomes darker. These changes result from an excess of melanin production, distribution, or transport which can be caused by various internal or external factors such as genetic predisposition, hormonal changes, inflammation, acne, ultraviolet (UV) exposure. Typical hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma and solar lentigos. This open, single-centre, three arm study is carried out with a new cosmetic formulation developed with the aim of acting on facial hyperpigmentation and used under normal conditions of use with before/after comparisons. This clinical trial is conducted in accordance with the protocol, the HELSINKI declaration (1964) and subsequent amendments, and/or the International Council on Harmonization (ICH) Good Clinical Practices (GCP) / and in compliance with applicable regulatory requirements. Statistical analysis: * Efficacy analysis: In each group, the quantitative parameters will be analyzed using a mixed-effect model. This model includes Time and baseline as fixed effects. Patient will be added as random effect. The comparisons between post-baseline time-point and baseline will be performed whatever the interaction results using a Dunnett adjustment. Degrees of freedom for the comparisons will be approximated by the Kenward-Roger method. * Safety analysis: No statistical analysis will be performed on safety. The data will be presented descriptively. Categorical data will be summarized using the number and percentage of patients in each category. Continuous data will be summarized using the arithmetic mean, Standard Deviation (SD), Q1, Q3, minimum, median and maximum values. Regarding the sample size determination, there was no formal calculation. A number of 24 patients in each group was considered sufficient to meet the study objective.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
COSderma
Wuhan, Hubei, China
Start Date
November 13, 2023
Primary Completion Date
March 5, 2024
Completion Date
March 5, 2024
Last Updated
July 1, 2024
67
ACTUAL participants
tested product
OTHER
Lead Sponsor
Cosmetique Active International
NCT06349447
NCT06320314
NCT07263841
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions